clavulanic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
beta-lactamase inhibitors	669	58001-44-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: clavulanic acid clavulanate clavulanate potassium clavulante potasium clavulanate potassium salt	A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase. Molecular weight: 199.16 Formula: C8H9NO5 CLOGP: -1.06 LIPINSKI: 0 HAC: 6 HDO: 2 TPSA: 87.07 ALOGS: 0.23 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

clavulanic acid
clavulanate
clavulanate potassium
clavulante potasium
clavulanate potassium salt

A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.

Molecular weight: 199.16
Formula: C8H9NO5
CLOGP: -1.06
LIPINSKI: 0
HAC: 6
HDO: 2
TPSA: 87.07
ALOGS: 0.23
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	43 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	31.38 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	75 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.22 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	3.10 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.91 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	0.90 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Aug. 6, 1984	FDA	DR REDDYS LABS INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Bronchiectasis	116.97	20.07	41	4354	10242	50590487
Bone erosion	111.84	20.07	41	4354	11646	50589083
Acute generalised exanthematous pustulosis	76.86	20.07	29	4366	8909	50591820
Hypothyroidism	75.16	20.07	43	4352	34082	50566647
Neutropenia	56.82	20.07	67	4328	147898	50452831
Anaphylactic reaction	54.89	20.07	42	4353	54013	50546716
Drug hypersensitivity	54.30	20.07	86	4309	250924	50349805
Nail dystrophy	44.65	20.07	11	4384	800	50599929
Loss of personal independence in daily activities	43.45	20.07	41	4354	70009	50530720
Hepatitis cholestatic	39.04	20.07	16	4379	6101	50594628
Cholecystitis chronic	38.04	20.07	18	4377	9651	50591078
Axillary pain	37.35	20.07	11	4384	1573	50599156
Jaundice	32.35	20.07	23	4372	26406	50574323
Pruritus	32.32	20.07	74	4321	283494	50317235
Catheter site haemorrhage	31.15	20.07	11	4384	2799	50597930
Toxic skin eruption	29.73	20.07	16	4379	11235	50589494
Red blood cell sedimentation rate abnormal	29.17	20.07	18	4377	16325	50584404
Hyperleukocytosis	29.15	20.07	7	4388	457	50600272
Cholestasis	28.57	20.07	21	4374	25380	50575349
Appendicitis	25.04	20.07	12	4383	6612	50594117
Synovitis	22.08	20.07	39	4356	123826	50476903
Thrombotic microangiopathy	21.84	20.07	12	4383	8779	50591950
Joint stiffness	21.22	20.07	19	4376	30289	50570440
Hyperchlorhydria	20.90	20.07	7	4388	1521	50599208
Meningitis aseptic	20.32	20.07	9	4386	4143	50596586

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular injury	89.68	26.57	43	2848	21200	29550436
Cholestasis	57.45	26.57	33	2858	23429	29548207
Urethral valves	54.89	26.57	11	2880	272	29571364
Spinal muscular atrophy	42.98	26.57	9	2882	278	29571358
Pneumococcal sepsis	42.64	26.57	11	2880	855	29570781
Anaphylactic shock	41.55	26.57	22	2869	13314	29558322
Anaphylactic reaction	40.35	26.57	28	2863	27545	29544091
Stevens-Johnson syndrome	37.18	26.57	22	2869	16475	29555161
Meningitis aseptic	35.59	26.57	12	2879	2364	29569272
Kounis syndrome	34.51	26.57	11	2880	1818	29569818
Ischaemic cerebral infarction	31.77	26.57	9	2882	996	29570640
Motor neurone disease	30.04	26.57	7	2884	356	29571280
Increased bronchial secretion	27.75	26.57	9	2882	1572	29570064

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anaphylactic reaction	92.31	18.52	66	6191	68598	64423877
Hepatocellular injury	88.66	18.52	55	6202	45180	64447295
Cholestasis	84.01	18.52	53	6204	44819	64447656
Acute generalised exanthematous pustulosis	73.59	18.52	33	6224	14025	64478450
Bone erosion	56.83	18.52	26	6231	11569	64480906
Meningitis aseptic	55.86	18.52	21	6236	5709	64486766
Bronchiectasis	51.91	18.52	26	6231	14114	64478361
Kounis syndrome	48.29	18.52	16	6241	3009	64489466
Anaphylactic shock	45.01	18.52	31	6226	30297	64462178
Jaundice	44.09	18.52	37	6220	48475	64444000
Stevens-Johnson syndrome	43.87	18.52	32	6225	34217	64458258
Nail dystrophy	43.41	18.52	11	6246	802	64491673
Spinal muscular atrophy	42.82	18.52	9	6248	285	64492190
Hepatitis cholestatic	40.69	18.52	21	6236	12134	64480341
Drug hypersensitivity	39.11	18.52	77	6180	237738	64254737
Pneumococcal sepsis	38.26	18.52	11	6246	1293	64491182
Pruritus	36.38	18.52	88	6169	312312	64180163
Axillary pain	35.18	18.52	11	6246	1721	64490754
Toxic epidermal necrolysis	33.05	18.52	28	6229	37138	64455337
Hypothyroidism	32.98	18.52	29	6228	40428	64452047
Liver injury	29.63	18.52	24	6233	29908	64462567
Jaundice cholestatic	29.07	18.52	15	6242	8655	64483820
Motor neurone disease	28.76	18.52	7	6250	432	64492043
Neutropenia	27.32	18.52	67	6190	239557	64252918
Clostridium difficile colitis	25.21	18.52	21	6236	27202	64465273
Aspartate aminotransferase increased	24.96	18.52	43	6214	119745	64372730
Bronchospasm	24.94	18.52	19	6238	21663	64470812
Catheter site haemorrhage	24.73	18.52	11	6246	4580	64487895
Stoma closure	24.67	18.52	5	6252	132	64492343
Respiratory tract infection bacterial	24.40	18.52	7	6250	816	64491659
Purpura	24.11	18.52	17	6240	17229	64475246
Increased bronchial secretion	22.65	18.52	9	6248	2833	64489642
Drug reaction with eosinophilia and systemic symptoms	22.46	18.52	27	6230	54190	64438285
Resuscitation	21.76	18.52	8	6249	2043	64490432
Ischaemic cerebral infarction	21.68	18.52	8	6249	2064	64490411
Bronchial disorder	21.52	18.52	8	6249	2107	64490368
Joint stiffness	21.26	18.52	20	6237	30384	64462091
Lower respiratory tract infection bacterial	21.18	18.52	6	6251	668	64491807
Rash	21.01	18.52	94	6163	458455	64034020
Cholangitis	20.80	18.52	13	6244	10789	64481686
Hepatitis acute	20.60	18.52	14	6243	13375	64479100
Sputum increased	20.52	18.52	9	6248	3626	64488849
Alanine aminotransferase increased	20.41	18.52	43	6214	138988	64353487
Toxic skin eruption	20.23	18.52	16	6241	19268	64473207
Cholecystitis chronic	19.98	18.52	12	6245	9275	64483200
Circulatory collapse	19.50	18.52	20	6237	33712	64458763
Brain injury	19.20	18.52	12	6245	9953	64482522
Disease complication	19.16	18.52	9	6248	4246	64488229
Hyperbilirubinaemia	18.89	18.52	16	6241	21189	64471286

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
FDA MoA	N0000000202	beta Lactamase Inhibitors
FDA EPC	N0000175930	beta Lactamase Inhibitor
CHEBI has role	CHEBI:35474	anti-anxiety agents
CHEBI has role	CHEBI:35625	beta-lactamase inhibitors
CHEBI has role	CHEBI:36047	antibacterial drugs
CHEBI has role	CHEBI:33281	antibiotics
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D065093	beta-Lactamase Inhibitors
MeSH PA	D004791	Enzyme Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Septicemia due to Escherichia coli	indication	9323009
Bacterial septicemia	indication	10001005	DOID:0040085
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Staphylococcal pneumonia	indication	22754005
Bacterial pneumonia	indication	53084003	DOID:874
Klebsiella cystitis	indication	60867007
Pneumonia due to Klebsiella pneumoniae	indication	64479007
Urinary tract infectious disease	indication	68566005
Haemophilus influenzae pneumonia	indication	70036007
Infection due to Escherichia coli	indication	71057007
Rhinoscleroma	indication	72409005	DOID:11336
Acute bacterial sinusitis	indication	75498004
Bacterial infection due to Klebsiella pneumoniae	indication	186435004
Pneumococcal pneumonia	indication	233607000
Escherichia coli urinary tract infection	indication	301011002
Bacterial urinary infection	indication	312124009
Infective otitis media	indication	312218008
Infection due to Staphylococcus aureus	indication	406602003
Osteomyelitis due to Staphylococcus aureus	indication	428783003
Pneumonia due to Staphylococcus aureus	indication	441658007
Sepsis due to Staphylococcus aureus	indication	448417001
Sepsis due to Pseudomonas	indication	448813005
Bacteroides Endometritis	indication
Pneumococcal Acute Otitis Media	indication
Haemophilus Parainfluenzae Pneumonia	indication
Pseudomonas Aeruginosa Urinary Tract Infection	indication
Klebsiella Endometritis	indication
Klebsiella Pneumoniae Peritonitis	indication
Haemophilus Influenzae Acute Otitis Media	indication
Moraxella Catarrhalis Pneumonia	indication
Moraxella Catarrhalis Acute Otitis Media	indication
Staphylococcus Aureus Joint Infection	indication
Staphylococcus Aureus Urinary Tract Infection	indication
E. Coli Peritonitis	indication
Enterobacter Endometritis	indication
Bacteroides Peritonitis	indication
Serratia Urinary Tract Infection	indication
Citrobacter Urinary Tract Infection	indication
Staphylococcus Endometritis	indication
E. Coli Endometritis	indication
Acute otitis media	off-label use	3110003
Pyrexia of unknown origin	off-label use	7520000
Chronic purulent otitis media	off-label use	38394007	DOID:14247
Cholangitis	off-label use	82403002	DOID:9446
Human bite - wound	off-label use	262555007
Chancroid	off-label use	266143009	DOID:13778
Diverticulitis of gastrointestinal tract	off-label use	271366000
Dog bite - wound	off-label use	283734005
Cat bite - wound	off-label use	283782004
Acute exacerbation of chronic bronchitis	off-label use	425748003
Pseudomonas Respiratory Tract Infection in Cystic Fibrosis	off-label use
Diabetic Foot Infection	off-label use
Obstruction of bile duct	contraindication	30144000
Kidney disease	contraindication	90708001	DOID:557
Disease of liver	contraindication	235856003	DOID:409
Infectious mononucleosis	contraindication	271558008	DOID:8568
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

Species	Use	Relation
Dogs	Urinary tract infections caused by Escherichia coli	Indication
Dogs	Skin and soft tissue infections caused by beta-lactamase producing Staphylococcus aureus	Indication
Dogs	Skin and soft tissue infections caused by Staphylococcus spp	Indication
Dogs	Skin and soft tissue infections caused by Streptococcus spp	Indication
Dogs	Skin and soft tissue infections caused by Escherichia coli	Indication
Dogs	Skin and soft tissue infections caused by Pasteurella spp	Indication
Cats	Urinary tract infections caused by Escherichia coli	Indication
Cats	Skin and soft tissue infections caused by beta-lactamase producing Staphylococcus aureus	Indication
Cats	Skin and soft tissue infections caused by Staphylococcus spp	Indication
Cats	Skin and soft tissue infections caused by Streptococcus spp	Indication
Cats	Skin and soft tissue infections caused by Escherichia coli	Indication
Cats	Skin and soft tissue infections caused by Pasteurella spp	Indication
Cats	Periodontal infections due aerobic and anaerobic bacteria	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
CLAVAMOX CHEWABLE Tablets, CLAVAMOX tablets	Zoetis Inc.	2
Clavamox Drops	Zoetis Inc.	2
Clavacillin	Dechra Veterinary Products LLC	2
Amoxicillin and Clavulanate Potassium for Oral Suspension	Dechra Veterinary Products LLC	2
Amoxicillin and Clavulanate Potassium Tablets	Cronus Pharma Specialities India Private Limited	2
Amoxicillin and Clavulanate Potassium for Oral Suspension	Cronus Pharma Specialities India Private Limited	2

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	3.07	acidic
pKa2	13.53	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Beta-lactamase TEM	Enzyme	BLAT_ECOLX	INHIBITOR	IC50	10.19	WOMBAT-PK	CHEMBL
Beta-lactamase	Enzyme	AMPC_ECOLI		IC50	7.82	CHEMBL
Beta-lactamase	Enzyme	Q59401_ENTCL		IC50	4	CHEMBL
Beta-lactamase SHV-1	Enzyme	BLA1_ECOLX		IC50	7.55	CHEMBL
Beta-lactamase	Enzyme	AMPC_ENTCL		Kd	6.40	CHEMBL
Beta-lactamase OXA-1	Enzyme	BLO1_ECOLX		IC50	5.49	CHEMBL
Beta-lactamase	Enzyme	AMPC_PSEAE		IC50	6.10	CHEMBL
Beta-lactamase	Enzyme	A4KCT8_9ENTR		IC50	8.05	CHEMBL
Beta-lactamase	Enzyme	A1E3K9_ECOLX		IC50	7.15	CHEMBL
Beta-lactamase	Enzyme	A8RR46_BACCS		IC50	7.07	CHEMBL
Carbapenem-hydrolizing beta-lactamase SFC-1	Enzyme	Q6JP75_SERFO		IC50	4.14	CHEMBL
Carbepenem-hydrolyzing beta-lactamase KPC	Enzyme	BLKPC_KLEPN		Ki	4.96	CHEMBL
Beta-lactamase	Enzyme	A2RP81_CITFR		IC50	7.17	CHEMBL
Beta-lactamase	Enzyme	Q9EXV5_ECOLX		IC50	8.05	CHEMBL
Beta-lactamase SHV-1	Enzyme	BLA1_KLEPN		IC50	6.77	CHEMBL
Beta-lactamase	Enzyme	Q6GWS8_ECOLX		IC50	5.07	CHEMBL
Beta-lactamase GES-13	Enzyme	D1MIX9_PSEAI		IC50	7	CHEMBL
Beta-lactamase	Enzyme	A0ZX81_KLEPN		IC50	5.76	CHEMBL
Beta-lactamase	Enzyme	Q4TVR4_KLEPN		IC50	7.70	CHEMBL
Class D beta-lactamase	Unclassified	Q50H31_BRAPL		IC50	5.70	CHEMBL
Beta-lactamase	Enzyme	Q2XPY6_SALET		IC50	8	CHEMBL
Beta-lactamase SHV-5	Enzyme	BLA5_KLEPN		Ki	4.60	CHEMBL
Beta-lactamase	Enzyme	D2SSQ3_PSEAI		IC50	7	CHEMBL
Beta-lactamase	Enzyme	Q3SAW3_PSEAI		IC50	7	CHEMBL
Beta-lactamase	Enzyme	BLAC_STAAU		MPC	8.72	WOMBAT-PK
Beta-lactamase	Enzyme	Q670S6_PSELU		IC50	7.44	CHEMBL

External reference:

ID	Source
N0000005804	NUI
D02370	KEGG_DRUG
61177-45-5	SECONDARY_CAS_RN
21216	RXNORM
4018406	VANDF
4019680	VANDF
C0055860	UMLSCUI
CHEBI:48947	CHEBI
J01	PDB_CHEM_ID
CHEMBL777	ChEMBL_ID
DB00766	DRUGBANK_ID
CHEMBL1003	ChEMBL_ID
D019818	MESH_DESCRIPTOR_UI
5280980	PUBCHEM_CID
4948	INN_ID
11128	IUPHAR_LIGAND_ID
23521W1S24	UNII
4463	MMSL
d04405	MMSL
002808	NDDF
002809	NDDF
395938000	SNOMEDCT_US
395939008	SNOMEDCT_US
412318009	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2270	TABLET, CHEWABLE	28.50 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2270	TABLET, CHEWABLE	28.50 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2272	TABLET, CHEWABLE	57 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2272	TABLET, CHEWABLE	57 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2274	TABLET, FILM COATED	125 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2274	TABLET, FILM COATED	125 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2275	TABLET, FILM COATED	125 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2275	TABLET, FILM COATED	125 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2277	POWDER, FOR SUSPENSION	28.50 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2277	POWDER, FOR SUSPENSION	28.50 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2279	POWDER, FOR SUSPENSION	57 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-2279	POWDER, FOR SUSPENSION	57 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-8675	POWDER, FOR SUSPENSION	42.90 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0093-8675	POWDER, FOR SUSPENSION	42.90 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0143-9249	TABLET	125 mg	ORAL	ANDA	28 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0143-9853	SUSPENSION	42.90 mg	ORAL	ANDA	28 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0143-9981	POWDER, FOR SUSPENSION	28.50 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0143-9982	POWDER, FOR SUSPENSION	57 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-1619	TABLET, CHEWABLE	28.50 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-1643	TABLET, CHEWABLE	57 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-1831	TABLET, FILM COATED	125 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-1852	TABLET, FILM COATED	125 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-1874	TABLET, FILM COATED	125 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	3	0781-1943	TABLET, MULTILAYER, EXTENDED RELEASE	62.50 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-6102	POWDER, FOR SUSPENSION	28.50 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-6104	POWDER, FOR SUSPENSION	57 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	0781-6139	SUSPENSION	42.90 mg	ORAL	ANDA	26 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	10544-931	TABLET, FILM COATED	125 mg	ORAL	ANDA	27 sections
Amoxicillin and Clavulanate Potassium	HUMAN PRESCRIPTION DRUG LABEL	2	10544-951	TABLET, FILM COATED	125 mg	ORAL	ANDA	26 sections
AMOXICILLIN AND CLAVULANATE POTASSIUM	HUMAN PRESCRIPTION DRUG LABEL	2	16590-019	TABLET, FILM COATED	125 mg	ORAL	ANDA	26 sections